Cargando…

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME

Detalles Bibliográficos
Autores principales:	Byalik, Tatyana, Tumyan, Gayane, Kokosadze, Natalia Natalia, Odzharova, Аkgul, Osmanov, Evgeny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430082/ http://dx.doi.org/10.1097/01.HS9.0000974608.86844.d4

Ejemplares similares

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1860: CLONALITY RELATEDNESS AND MOLECULAR CHARACTERISTICS OF RICHTER SYNDROME
por: Sha, Y., et al.
Publicado: (2022)

PB2009: OPPORTUNITIES OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WITH DIALYSIS-DEPENDENT RENAL IMPAIRMENT
por: Kliuchagina, I., et al.
Publicado: (2022)

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
por: Shadman, M., et al.
Publicado: (2022)

PB1882: RICHTER TRANSFORMATION FEATURES, SURVIVAL AND TREATMENT OUTCOME IN HEMATOLOGY CLINIC OF CRAIOVA, ROMANIA
por: Rotaru, I., et al.
Publicado: (2022)

PB1876: ACALABRUTINIB RELATED INFECTIOUS COMPLICATIONS-A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHASE III RCT
por: Parmar, K., et al.
Publicado: (2022)

PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
por: Innocenti, Idanna, et al.
Publicado: (2023)

PB2259: THE NEW PD-1 INHIBITOR PROLGOLIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
por: Semenova, Anastasia, et al.
Publicado: (2023)

PB1925: NAOS STUDY: FIRST INTERIM ANALYSIS OF ACALABRUTINIB USE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN A REAL-LIFE SETTING.
por: Quinquenel, Anne, et al.
Publicado: (2023)

PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL.
por: Burger, J., et al.
Publicado: (2022)

PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL
por: Yang, Shenmiao, et al.
Publicado: (2023)

PB1881: IBRUTINIB REDUCES THE RISK OF RICHTER’S TRANSFORMATION IN PREVIOUSLY TREATED CLL PATIENTS: A POPULATION-BASED STUDY IN BRITISH COLUMBIA
por: Ramadan, R., et al.
Publicado: (2022)

PB2309: OUTCOMES OF 22 PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: SINGLE INSTITUTE EXPERIENCE
por: Tumyan, Gayane, et al.
Publicado: (2023)

PB1930: EPIC: A NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH FIRST-LINE ACALABRUTINIB THROUGH THE UK EARLY ACCESS PROGRAMME. INTERIM ANALYSIS UP TO 24 MONTHS
por: Eyre, Toby, et al.
Publicado: (2023)

PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL
por: Sharp, A., et al.
Publicado: (2022)

PB1756: INOTUZUMAB OZOGAMICIN IN THERAPY RELAPSE/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL): A SINGLE CENTER EXPERIENCE
por: Antipova, A., et al.
Publicado: (2022)

PB2700: ANXIETY AND DEPRESSION IN HEMATOLOGICAL MALIGNANCIES PATIENTS: FOCUS ON TREATMENT ADHERENCE
por: Vybornykh, Dmitry E, et al.
Publicado: (2023)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Korsakova, Natalia, et al.
Publicado: (2023)

PB2448: RESTORATION OF HEMOGRAM PARAMETERS IN PATIENTS WITH HEMOBLASTOSIS AFTER TRANSPLANTATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS
por: Natalia, Isaeva, et al.
Publicado: (2023)

PB1836: LOSS OF HETEROZYGOSITY IN AML PATIENTS WITH INV(16)
por: Bessmertniy, Dmitry, et al.
Publicado: (2023)

PB2171: POTENTIAL ROLE OF FACTOR XII POLYMORPHISM IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Efremova, Elizaveta, et al.
Publicado: (2023)

PB2030: HYPERCHROMIC ANEMIA AS THE FIRST MANIFESTATION OF MYELOPROLIFERATIVE DISEASE
por: Lepkov, Sergey, et al.
Publicado: (2023)

PB2119: REDUCED OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS DURING THE COVID-19 PANDEMIC
por: Luchinin, Alexander, et al.
Publicado: (2023)

PB2282: MEK-KINASE INHIBITOR (TRAMETINIB) AS A TREATMENT OPTION FOR HAIRY CELL LEUKEMIA
por: Smirnova, Svetlana, et al.
Publicado: (2023)

PB2477: INTEGRATION OF OPTICAL GENOME MAPPING IN DAILY CYTOGENETICS LABORATORY ROUTINE.
por: Díaz González, Álvaro, et al.
Publicado: (2023)

PB1997: TRISOMY 18 IN MYELODYSPLASTIC SYNDROMES
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2023)

PB2055: PREGNANCY IN PATIENTS WITH APLASTIC ANEMIA – CLINICAL OBSERVATIONS
por: Shilova, Elene, et al.
Publicado: (2023)

PB2313: THE PROGNOSTIC SIGNIFICANCE OF APOPTOSIS-INDUCING FACTOR IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Vaneeva, Elena, et al.
Publicado: (2023)

PB2293: HARNESSING ACCELERATED SEQUENTIAL EVANS SYNDROME
por: Almakadi, M., et al.
Publicado: (2022)

PB2253: HYPEREOSINOPHILIC SYNDROMES: CARDIAC EMERGENCY IN THE ELDERLY
por: Gougas, Ahlam, et al.
Publicado: (2023)

PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY
por: Corry, Sorcha, et al.
Publicado: (2023)

PB2683: MODERN DIAGNOSTIC CAPABILITIES OF THE OPHTHALMOLOGICAL STATUS OF PATIENTS WITH ONCO-HEMATOLOGICAL DISEASES.
por: Yusef, Yusef N, et al.
Publicado: (2023)

PB2705: PROFESSIONAL BURNOUT AMONG HEMATOLOGISTS AFTER THE OUTBREAK OF THE COVID-19 PANDEMIC AND ASSOCIATED FACTORS
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

PB2008: CUTANEOUS HEMORRHAGIC SYNDROME IN PATIENTS WITH AL-AMYLOIDOSIS
por: Khyshova, V., et al.
Publicado: (2022)

PB2015: DIAGNOSIS, CLASSIFICATION AND STRATIFICATION OF MYELODYSPLASTIC SYNDROMES IN ALGERIA
por: Moussa, Yamina Bouchakour, et al.
Publicado: (2023)

PB2020: OUTCOMES OF PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES
por: Amor, Imen Ben, et al.
Publicado: (2023)

PB2058: IMPACT OF COMORBIDITIES AND RESPONSE TO TREATMENT ON THE MPN SAF ASSESSMENT OF PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE SYNDROMES.
por: Mohamed, B., et al.
Publicado: (2022)

PB1916: SOMATIC MUTATIONS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME IN RUSSIAN PATIENTS
por: Kohno, A., et al.
Publicado: (2022)

PB1918: MOLECULAR CHARACTERIZATION AND CLINICAL RELEVANCE OF ERYTHROPOIESIS IN MIELODYSPLASTIC SYNDROMES.
por: Villalba, A., et al.
Publicado: (2022)

PB2602: POPULATION-BASED STUDY OF HEMOLYTIC UREMIC SYNDROME HOSPITALIZATIONS.
por: Jhaveri, Khushali, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2ccgg91qbub4osbn9lr51ebeg9